• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » The History of Depakote

The History of Depakote

July 1, 2008
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Valproate originally saw the light of day in the German laboratory of Beverly Burton, in 1882. She was engaged in research on fatty acids, and synthesized a new one, called 2-propylvaleric acid. But she was not able to make this acid into a salt, which is necessary in order to turn it into a solid form, and so she stopped working on it. The compound resurfaced in the 1940s when German scientists were working on creating food substitutes as part of the war effort. They succeeded in turning coal into a mixture of triglycerides that tasted a bit like butter, and they called it ersatzbutter. In analyzing this promising substance, they isolated the same acid that Beverly Burton had discovered in 1882. They gave it a new name, valproic acid. It turned out that it was not very useful as a nutritional supplement, however, because most of it was excreted unchanged. However, it was useful as a solvent, and it found use as a way of dissolving other drugs for research in laboratories. Fast forward to 1960, in a pharmacology laboratory at the University of Grenoble. Pierre Eymard was trying to develop a plant derivative called khelline as an antispasmodic. But he kept facing a stumbling block – khelline was very hard to dissolve. He learned about the wonderful solvent effects of valproic acid, and used it to dissolve khelline. When he injected this mixture into patients, it produced profound relaxation, leading Eymard’s supervisor, Carraz, to screen valproic acid for behavioral effects. Carraz added sodium to it, creating sodium valproate, eventually doing studies of epileptics, leading to its first wide clinical use as an anticonvulsant.

In 1983, Abbott obtained a license for its use in the U.S., and came up with a new way of making the salt – by adding another sodium ion, turning it into sodium divalproate. They received a patent for this, because they successfully argued that it was easier on the stomach than valproic acid. Eventually, “Depakote” received FDA approval for the treatment of both epilepsy and bipolar disorder.

Source: David Healy, Mania: A Short History of Bipolar Disorder. Baltimore: The Johns Hopkins University Press, 2008.
General Psychiatry
KEYWORDS pharmacology
www.thecarlatreport.com
Issue Date: July 1, 2008
SUBSCRIBE NOW
Table Of Contents
Antidepressants and Bipolar Disorder: An Update
Lamictal: What is it Good For?
Weight Gain and Mood Stabilizers
The Case in Favor of the Bipolar Spectrum
Is Bipolar Disorder Overdiagnosed?
SSRIs show weak advantage over bupropion for anxious depression
Computer as psychotherapist?
The History of Depakote
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto84222831.jpg
    General Psychiatry

    The Adderall Shortage

    Adderall is in short supply, and the backlog is having a domino effect on other stimulants. Find out why, and how long it will last.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.